157 related articles for article (PubMed ID: 24650640)
1. Discovery of 4-anilino α-carbolines as novel Brk inhibitors.
Mahmoud KA; Krug M; Wersig T; Slynko I; Schächtele C; Totzke F; Sippl W; Hilgeroth A
Bioorg Med Chem Lett; 2014 Apr; 24(8):1948-51. PubMed ID: 24650640
[TBL] [Abstract][Full Text] [Related]
2. Novel 4-anilino-α-carboline derivatives induce cell death in nonadhesive breast cancer cells through inhibition of Brk activity.
Oelze M; Mahmoud KA; Sippl W; Wersig T; Hilgeroth A; Ritter CA
Int J Clin Pharmacol Ther; 2015 Dec; 53(12):1052-5. PubMed ID: 26396134
[No Abstract] [Full Text] [Related]
3. Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors.
Zeng H; Belanger DB; Curran PJ; Shipps GW; Miao H; Bracken JB; Arshad Siddiqui M; Malkowski M; Wang Y
Bioorg Med Chem Lett; 2011 Oct; 21(19):5870-5. PubMed ID: 21855335
[TBL] [Abstract][Full Text] [Related]
4. Computational & experimental evaluation of the structure/activity relationship of β-carbolines as DYRK1A inhibitors.
Drung B; Scholz C; Barbosa VA; Nazari A; Sarragiotto MH; Schmidt B
Bioorg Med Chem Lett; 2014 Oct; 24(20):4854-60. PubMed ID: 25240617
[TBL] [Abstract][Full Text] [Related]
5. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
[TBL] [Abstract][Full Text] [Related]
6. Optimization, pharmacophore modeling and 3D-QSAR studies of sipholanes as breast cancer migration and proliferation inhibitors.
Foudah AI; Sallam AA; Akl MR; El Sayed KA
Eur J Med Chem; 2014 Feb; 73():310-24. PubMed ID: 24487236
[TBL] [Abstract][Full Text] [Related]
7. Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors.
Jiang J; Gui F; He Z; Li L; Li Y; Li S; Wu X; Deng Z; Sun X; Huang X; Huang W; Han S; Zhang T; Wang Z; Jiao B; Song S; Wang H; Chen L; Zhou D; Liu Q; Ren R; Zhang J; Deng X
Cancer Res; 2017 Jan; 77(1):175-186. PubMed ID: 27758886
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 4-benzylamino-substituted α-carbolines as a novel class of receptor tyrosine kinase inhibitors.
Krug M; Wichapong K; Erlenkamp G; Sippl W; Schächtele C; Totzke F; Hilgeroth A
ChemMedChem; 2011 Jan; 6(1):63-72. PubMed ID: 21140395
[TBL] [Abstract][Full Text] [Related]
9. 4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors.
Zhang N; Wu B; Boschelli DH; Golas JM; Boschelli F
Bioorg Med Chem Lett; 2009 Sep; 19(17):5071-4. PubMed ID: 19632113
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and antitumoral activity of novel 3-(2-substituted-1,3,4-oxadiazol-5-yl) and 3-(5-substituted-1,2,4-triazol-3-yl) beta-carboline derivatives.
Formagio AS; Tonin LT; Foglio MA; Madjarof C; de Carvalho JE; da Costa WF; Cardoso FP; Sarragiotto MH
Bioorg Med Chem; 2008 Nov; 16(22):9660-7. PubMed ID: 18951806
[TBL] [Abstract][Full Text] [Related]
11. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
Davis GD; Vasanthi AH
Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
[TBL] [Abstract][Full Text] [Related]
12. Discovery of tetrahydro-beta-carbolines as inhibitors of the mitotic kinesin KSP.
Liu F; Yu LQ; Jiang C; Yang L; Wu WT; You QD
Bioorg Med Chem; 2010 Jun; 18(12):4167-77. PubMed ID: 20537544
[TBL] [Abstract][Full Text] [Related]
13. The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer.
Lippa B; Kauffman GS; Arcari J; Kwan T; Chen J; Hungerford W; Bhattacharya S; Zhao X; Williams C; Xiao J; Pustilnik L; Su C; Moyer JD; Ma L; Campbell M; Steyn S
Bioorg Med Chem Lett; 2007 Jun; 17(11):3081-6. PubMed ID: 17398092
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of novel 3,9-substituted β-carboline derivatives as anticancer agents.
Chen YF; Lin YC; Chen JP; Chan HC; Hsu MH; Lin HY; Kuo SC; Huang LJ
Bioorg Med Chem Lett; 2015 Sep; 25(18):3873-7. PubMed ID: 26235951
[TBL] [Abstract][Full Text] [Related]
15. The design, synthesis and biological evaluation of 7-alkoxy-4-heteroarylamino-3-cyanoquinolines as dual inhibitors of c-Src and iNOS.
Cao X; You QD; Li ZY; Liu XR; Xu D; Guo QL; Shang J; Chern JW; Chen ML
Bioorg Med Chem Lett; 2008 Dec; 18(23):6206-9. PubMed ID: 18930653
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src.
Plé PA; Green TP; Hennequin LF; Curwen J; Fennell M; Allen J; Lambert-Van Der Brempt C; Costello G
J Med Chem; 2004 Feb; 47(4):871-87. PubMed ID: 14761189
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitors.
Wu B; Wang HL; Cee VJ; Lanman BA; Nixey T; Pettus L; Reed AB; Wurz RP; Guerrero N; Sastri C; Winston J; Lipford JR; Lee MR; Mohr C; Andrews KL; Tasker AS
Bioorg Med Chem Lett; 2015 Feb; 25(4):775-80. PubMed ID: 25616902
[TBL] [Abstract][Full Text] [Related]
18. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
19. 7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.
Huber K; Brault L; Fedorov O; Gasser C; Filippakopoulos P; Bullock AN; Fabbro D; Trappe J; Schwaller J; Knapp S; Bracher F
J Med Chem; 2012 Jan; 55(1):403-13. PubMed ID: 22136433
[TBL] [Abstract][Full Text] [Related]
20. Recent insights into synthetic β-carbolines with anti-cancer activities.
Kumar S; Singh A; Kumar K; Kumar V
Eur J Med Chem; 2017 Dec; 142():48-73. PubMed ID: 28583770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
